Mizuho raised the firm’s price target on Boston Scientific to $90 from $85 and keeps a Buy rating on the shares after meeting with management. The firm says high-level feedback suggests that Boston Scientific’s Cardiology segment is poised to maintain a “healthy” double-digit sales growth profile for the foreseeable future. It cites upside combo surgery scenarios for the higher target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Welcomes New Director and Updates Governance
- Catheter Precision appoints Marie-Claude Jacques as CCO
- Boston Scientific price target raised to $78 from $70 at Barclays
- Upcoming Deadline to Share in Boston Scientific Corporation (BSX) Class Action Settlement
- Boston Scientific price target raised to $82 from $78 at RBC Capital
